Kingsley H. Nelson

Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

James M. Apgar, Robert R. Wilkening, Dann L. Parker et al. · Bioorganic & Medicinal Chemistry Letters · 2020 · 48 citations

Medicine, Immunology, Pharmacotherapy +4

Synthesis and structure–activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists

J. Robert Merritt, Laura L. Rokosz, Kingsley H. Nelson et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 46 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Medicine +4

A chemoselective rhodium(II) mediated solid phase 1,3-dipolar cycloaddition and its application to a thermally self-cleaving furan scaffold

Darren L. Whitehouse, Kingsley H. Nelson, Sergey N. Savinov et al. · Tetrahedron Letters · 1997 · 43 citations · Full text

Materials Science, Inorganic Chemistry, Chemical Engineering +13

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase

Brian Heasley, Gregory J. Pacofsky, Ahmed Mamai et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 33 citations

Medicinal Chemistry, β-1,3-Glucan Synthase, Antifungal Agent +10

Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin

James M. Apgar, Robert R. Wilkening, Mark L. Greenlee et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 32 citations · Full text

Biochemistry, Medicine, Active Inhibitors +7